Aug 03, 2021 7:45am EDT

Complete Response Letter Received from FDA for Treosulfan

Jul 19, 2021 7:40am EDT

Medexus Appoints New Chief Financial Officer

Jul 12, 2021 9:29am EDT

Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in Canada

Jun 28, 2021 4:30pm EDT

Medexus Receives Notice of Compliance to Commercialize Treosulfan in Canada

Jun 16, 2021 5:00pm EDT

Medexus Revenue Increases 43.5% to a Record US$79.7 Million for Fiscal 2021

Jun 15, 2021 4:05pm EDT

Medexus Announces Graduation to the Toronto Stock Exchange

Jun 14, 2021 8:30am EDT

Medexus to Present at Raymond James Human Health Innovation Conference

Jun 11, 2021 8:30am EDT

Medexus Schedules Fiscal Year 2021 Conference Call

Jun 10, 2021 8:30am EDT

Medexus Strengthens Medical Affairs Team in Preparation for Planned Treosulfan Launch

Jun 09, 2021 8:30am EDT

Medexus Announces Availability of Triamcinolone Hexacetonide in the United States